Regulatory FDA approves AstraZeneca’s Saphnelo for SLE Pharmaceutical TechnologyAstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE.Immunology & InflammationRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaceutical Technology AstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Oruka surges as long-acting psoriasis drug shows early promiseNext: BioMarin acquires Amicus Therapeutics for $4.8bn Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
